Kraig Biocraft Laboratories, Inc.
Datakwaliteit: 83%
KBLB
OTC
Manufacturing
Chemicals
€ 0,14
▲
€ 0,01
(6,15%)
Marktkapitalisatie: 151,77 M
Prijs
€ 0,14
Marktkapitalisatie
151,77 M
Dagbereik
€ 0,13 — € 0,14
52-Weeksbereik
€ 0,07 — € 0,15
Volume
616.710
Openen € 0,13
50D / 200D Gem.
€ 0,11
26,61% above
50D / 200D Gem.
€ 0,09
51,65% above
Quick Summary
Belangrijkste Punten
Negative free cash flow of -1,79 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio0,16
Interest Coverage-5,91
Waardering
PE (TTM)
-41,89
Onder sectorgemiddelde (-1,98)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -41,9 | -2,0 |
| P/B | — | 5,1 |
| ROE % | — | -51,0 |
| Net Margin % | — | -150,2 |
| Rev Growth 5Y % | — | 9,3 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -3,62 M |
| ROE | N/A | ROA | -183,56% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -1,79 M |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,16 |
| Interest Coverage | -5,91 | Asset Turnover | N/A |
| Working Capital | -8,54 M | Tangible Book Value | -7,96 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -41,89 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -1,18% | ||
| Market Cap | 151,77 M | Enterprise Value | 150,21 M |
| Per Share | |||
| EPS (Diluted TTM) | 0,00 | Revenue / Share | N/A |
| FCF / Share | 0,00 | OCF / Share | 0,00 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 49,52% |
| SBC-Adj. FCF | N/A | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -3,62 M | -3,40 M | -3,03 M | -3,84 M | -8,05 M |
| EPS (Diluted) | 0,00 | 0,00 | 0,00 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -3,37 M | -3,07 M | -2,61 M | -2,12 M | -2,76 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 165.758,0 | 164.374,0 | 237.871,0 | 176.431,0 | 197.745,0 |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 570.709,0 | 529.603,0 | 153.955,0 | 153.955,0 | 238.110,0 |
| Income Tax | — | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2,57 M | 1,51 M | 3,23 M | 4,57 M | 3,02 M |
| Total Liabilities | 10,56 M | 9,65 M | 8,94 M | 8,09 M | 8,32 M |
| Shareholders' Equity | -8,00 M | -8,15 M | -5,71 M | -3,52 M | -5,30 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 1,79 M | 673.264,0 | 2,55 M | — | — |
| Current Assets | 1,87 M | 740.285,0 | 2,57 M | 3,98 M | 2,37 M |
| Current Liabilities | 10,45 M | 9,61 M | 8,89 M | 8,07 M | 8,16 M |
{"event":"ticker_viewed","properties":{"ticker":"KBLB","listing_kind":"stock","pathname":"/stocks/kblb","exchange":"OTC","country":"US"}}